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Abstract: 
Despite significant advances in pharmaceutical and biotechnological drug discovery, the 
global population is plagued with many challenging diseases. These are further compounded 
by anticipated explosion in an ageing population, which presents several problems such as 
polypharmacy, dysphagia and neurological conditions, resulting in non-compliance and 
disease complications. For antibiotics, poor compliance, can result in development of drug 
resistant infections which can be fatal.  Further, children, especially, in developing countries 
die unnecessarily from easily treatable diseases (e.g. malaria), due to poor compliance arising 
from bitter taste and inability to swallow currently available medication. Though, some of 
these challenges require the discovery of new drug compounds, a significant number can be 
resolved by employing pharmaceutics approaches to reduce the incidence of poor patient 
compliance. Such solutions are expected to make swallowing easier and reduce the need to 
swallow several solid medications, which is difficult for vulnerable pediatric and geriatric 
patients. This commentary will explore the current state of the art in the use of drug delivery 
innovations to overcome some of these challenges, taking cues from relevant regulatory 
agencies such as the Food and Drugs Administration, the European Medicines Agency, 
World Health Organization and the peer reviewed scientific and clinical literature. 
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1. Overview 
Within the last few decades, science has made significant advances which have led to major 
medical and pharmaceutical breakthroughs. However, despite the many scientific, medical 
and pharmaceutical breakthroughs such as antibiotics and vaccinations, the global population 
continues to be plagued with significant health challenges. Clinicians still face the huge 
problem of antibiotic resistant bacteria which are not sensitive to current first line antibiotics. 
In the developed world, improved medical advancements means that most people live longer 
than a few decades, which has however, created new clinical challenges. On the other hand, 
developing countries are plagued by several neglected diseases including malaria, which 
affects mostly the pediatric population who are the most vulnerable, just like the geriatric 
populations in developed countries. These are compounded by the increasingly reduced 
number of ‘block-buster’ drugs coming through the pharmaceutical drug development 
pipeline, coupled with the increasing cost of global healthcare and high population explosions 
worldwide.  
 
2. General pharmaceutical challenges 
The pharmaceutical industry spends significant amounts of time and money in drug discovery 
efforts to develop and bring new drug products to market. However, these efforts are plagued 
with several challenges even with new compounds that are potentially active in the target site 
but fail to reach market. Such drugs fail mainly because of poor solubility which makes it 
difficult to be absorbed into the systemic circulation when administered, especially via the 
most commonly used oral gastro intestinal route. This is important, as sufficient solubility of 
the unionized form of the drug, coupled with appropriate partition coefficient, is essential to 
ensure absorption, systemic bioavailability and ultimately determines therapeutic efficacy.  
 In addition, a drug typically administered via the oral route, will go through several 
absorption barriers with corresponding drug loss before reaching the intended site of action, 
and therefore require higher initial dose to be administered than that required at the site of 
action, as summarized in Figure 1. Furthermore, most new drugs that successfully make it to 
development stage, face the challenge of bitter and unpleasant taste when administered via 
the oral route which presents significant challenges in terms of patient non-compliance and 
subsequently, low therapeutic outcomes, especially for pediatric patients. This requires added 
research and formulation development efforts to address such challenges.  These can result in 
increased product costs, which ultimately affects the patient and health providers worldwide. 
In addition, advances in molecular biology, genomics and proteomics, have resulted in the 
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development of pharmaceutical biotechnology based large molecules such as peptides and 
proteins, which are difficult to administer via the traditional GIT route due to instability in the 
GI pH, proteolytic enzymes and significant first pass effect in the liver. Such complex 
molecules are therefore largely administered via the parenteral route (i.e. injections) which is 
a challenge for children and patients with chronic conditions such as diabetes, where regular 
injections are required but which is invasive and painful. The commonly used traditional 
routes of administration and their advantages and disadvantages have been summarized in 
Table 1. 
 
FIGURE 1 HERE 
 
 
TABLE 1 HERE 
 
3 Global health challenges 
As noted above, global health challenges vary depending on the geographical and / economic 
region of the world.  
 
3.1 Geriatric populations 
Most developed countries with better nutrition, advanced medical facilities and better patient 
care generally have higher life expectancy and therefore generally an ageing population, with 
most projected to live beyond 65 years old. This presents unique challenges as older patients 
suffer from multiple diseases including neurological ones such as dementia and dysphagia. 
Compared to the general adult population (18 – 60 years), medicines and medication 
management are much more complex and challenging in the elderly (over 65 years) with the 
latter generally requiring different features than standard adult medications. In addition, the 
presence of several chronic disease conditions results in multiple therapies which require the 
administration of many medications. Further, most diseases of older people are chronic, 
requiring them to take their medication over prolonged periods. The presence of multiple 
medical conditions (Table 2) and prolonged medication results in another therapeutic 
problem which is the challenge of polypharmacy, where patients take more than 5 different 
types of medication in a day with different instructions. This is obviously difficult for 
dementia patients and will need to depend on carers or find other means of differentiating the 
various medications and administering them appropriately. In most cases, such medication 
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present in the form of tablets or capsules, which are difficult to swallow for patients with 
dysphagia, who stand the risk of choking. For example, older patients with chronic heart 
conditions and risk of thrombosis, take aspirin tablets daily which is clearly a challenge for 
those with swallowing difficulties. The European Medicines Agency (EMA) has identified 
the following problem statement: “Elderly patients may face physical and cognitive 
impairment and hence they may have difficulties in taking their medicines e.g. swallowing 
tablets, opening packaging or reading the user instruction and patient information leaflet. 
Older people may also more frequently require the assistance of caregivers than the overall 
adult population. In addition, physiological changes such as hepatic impairment, renal 
impairment or altered gastrointestinal motility may require a re-evaluation of the benefit/risk 
profile of the medicine and warrant adapted dosing regimens. The pharmaceutical 
development of medicines for use by older patients should take such aspects into 
consideration.”
 5
 
These present several age-related limitations which cause non-compliance and therefore poor 
health outcomes. Though this can be resolved with fast disintegrating tablets that disperse 
readily in water for drinking, high liquid volumes can still be difficult for dysphagia patients, 
especially the highly infirm and bed bound, where the risk of vomiting is high. Further, liquid 
formulations tend to leave a bitter after taste, even when sweeteners are present.  The ultimate 
outcome is poor uptake and acceptance. Swallowing issues will therefore have a direct impact 
on medication adherence. Swallowing difficulties have been described as a major health care 
problem in elderly that advances with increasing age, affecting 50% of patients in nursing 
homes
 6
. For example: 
a. Most older adults have less than 20 teeth which makes chewing very difficult, 
therefore chewable tablets though a good alternative to swallowing, presents 
difficulties for such patients. 
b. Effervescent tablets require the need to disperse in water which though better than 
tablets, do not always lend themselves to easy swallowing whilst tablets such as 
Vitamin D is a fat soluble vitamin will not dissolve in water and will require an 
emulsion such as milk. 
Based on the general literature, it is quite evident that there is need for alternative 
formulations to tablets or capsules that are easy to swallow without the need for 
reconstitution with lots of water or chewing. Such formulations are expected to result in ease 
of acceptance and uptake by patients, carers and doctors with a resultant attainment of high 
patient compliance. Liu and co-workers have suggested the use of fast melt formulations such 
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as films and wafers for geriatric drug delivery as an alternative to traditional tablets, capsules 
and effervescent powders. However, most of these reports are based on normal adult data 
which is non- specific
 7
.  
 
TABLE 2 HERE 
 
3.2 Pediatric populations   
There are also similar challenges associated with treatments available for pediatric 
populations most of whom struggle to swallow tablets and capsules, and more acutely, have 
an innate resistance of injections due to the pain and the fear of needles which results in 
significant patient non-compliance. Whilst most children’s medicines come in the form of 
liquids or suspensions which are more easily swallowed, these are not practical in cases of 
vomiting. More importantly, these require the need for masking of bitter taste and unpleasant 
smells of some active ingredients, which also result in patient non-compliance. Current 
approaches using high sugar concentrations and sweeteners present dental, obesity and type 2 
diabetes concerns. Poor patient compliance in pediatric patients is of particular concern in 
neglected diseases such as malaria which are common in developing countries where the 
infant mortality rates from such non- compliance is high. Some of the common pediatric 
conditions and the current associated therapies are shown in Table 3. 
 In 2007, the WHO
8
 launched an initiative “Make medicine child size” with aimed to 
raise awareness and accelerate action on providing access to child – specific medicines. In the 
same year, the European Pediatric Formulation Initiative (EuPFI) was established in London 
to help promote the preparation of effective and safe children medication by facilitating 
sharing of expertise between key stakeholders including academic researchers, industry, 
clinical and regulatory professionals. Its key objectives include identifying the common 
challenges encountered with developing formulations for pediatric populations to achieve 
better medications and dosage forms that are clinically relevant for children. The European 
Regulation on Pediatric Medicines
9
, now requires suitable dosage forms for children, 
particularly small children, to be developed by a pharmaceutical company as part of their 
pediatric investigation plan
10
. 
 The WHO model formulary for children provides independent prescriber information 
on dosage and treatment guidance for medicines based on the WHO model list of essential 
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medicines for pediatrics. The desirable features that are essential and need to be taken into 
consideration when designing pediatric dosage forms include: 
• Convenient, reliable administration and preferably ready-to-use formulations 
• Minimal manipulation by health care professionals, parents or caregivers 
• Dose and dose volume/weight adjusted to the intended age group 
• Acceptable and palatable dosage form 
• Minimum dosing frequency 
• Minimal impact on life style 
• Minimum, non-toxic excipients 
• Transportable and low bulk/weight 
• Easy to produce and stable in a variety of climates 
• Affordable 
• Commercially viable
10
 
 
TABLE 3 HERE 
 
Some of the above features are considered for certain pediatric drugs such as dose and dosage 
volume, while others such as transport, weight and affordability address end–user needs in 
developing countries. The design and selection of new pharmaceutical dosage forms involves 
the careful consideration and a balance between quality target product profile versus technical 
challenges and development feasibility. Pediatric dosage forms present particular complexity 
due to the diverse patient population, compliance challenges and safety consideration 
amongst this vulnerable patient group. The pediatric population is divided into six groups 
such as; pre-term new-born infants, term new-born infants, infants/toddlers, pre-school 
children, school children and adolescents
11
. Further challenges include size and physiological 
and biological maturation, difficulties and low tolerance to unacceptable taste, specific 
concerns associated with required excipients
12
.   
 In a recent study on behalf of the EuPFI, Batchelor and co-workers surveyed global 
experts in pediatric biopharmaceutics from academia, healthcare professionals, 
pharmaceutical industry scientists and regulators to understand the current views around the 
development of a pediatric biopharmaceutics classification system (pBCS), something which 
is currently lacking in the state of the art of pediatric formulation and drug delivery
13
. They 
found that there was concern, especially in the area of defining of BCS for class II and class 
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IV drugs. The authors concluded that further cross disciplinary discussion and research is 
required into evidence that will underpin the development of a suitable pediatric BCS. 
 Drug therapy plays a vital role in disease management for pediatric populations 
suffering from a variety of acute and chronic diseases. The majority of drugs approved for 
adults, however, have not been approved for use in children though such medicines are 
commonly used in pediatric patients. One of the most important impediments for their 
application however, is the lack of suitable alternative pediatric dosage forms
14
. As a result, 
many drugs used in pediatric populations are not available in suitable dosage forms such as 
thin films and must be prepared extemporaneously, while using appropriate excipients. 
However, it is essential to determine the stability of various drugs at clinically important 
concentrations and safe practical storage conditions.      
 
3.3 Common routes of drug administration for pediatric and geriatric populations 
Generally, drug administration occurs via various routes with varying degrees of benefits and 
drawbacks. Over the last few decades, administration of drugs in the human body has been 
the main area of research and different types of routes have been exploited as described in 
Table 4 The rejection rate of oral dosage forms is higher than other routes (topical, 
intravenous, intramuscular), due to the unpleasant and bitter taste of the medicine
15
 as 
previously noted. Administration of drug to pediatric patients’ body is always a challenge as 
pediatric dosage forms require accurate doses based on the age and body weight
16
. Oral 
mucosa (buccal) thin films offer easy administration and handling, can provide rapid 
disintegration and dissolution or sustained release, bypasses first-pass metabolism, enhanced 
stability and taste masking for bitter drugs, local and systematic drug delivery, rapid onset of 
action, and no trained or professional person is required for pediatric administration
17
. 
 
TABLE 4 HERE 
 
4 Tropical diseases: Malaria as a test case 
Most tropical diseases are commonly found in developing countries in Africa, Asia and the 
Americas and usually linked with poverty and its associated social challenges such as poor 
housing and sanitation as well as inadequate healthcare facilities and poor public health 
provision. Most of these diseases are poorly managed and have been officially designated as 
neglected tropical diseases (NTDs) by the WHO.
18
 One other well-known tropical disease is 
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malaria which though receives a lot of current global attention, still poses significant threats 
to the endemic areas and even tourists who visit such places.  
 Malaria is caused by infection of red blood cells with protozoan parasites of 
Plasmodium through feeding bites by the female anopheles mosquito. The most common 
human Plasmodium species include P. falciparum, P. vivax, P. ovale and P. malariae, 
depending on the region of the world. The burden of malaria remains a significant public 
health challenge in Sub-Saharan Africa with reported incidents of morbidity and deaths 
arising from plasmodial infections. In 2010, 91% of the 655,000 global deaths due to malaria 
occurred in Africa and 86% of these cases occurred in children below the age of five
18
. 
According to the WHO, “there were an estimated 438, 000 malaria deaths in the world, of 
which approximately 69% were children under the age of 5 years”.
 18
 Though proven 
treatment options for malaria are fully documented, poor palatability and associated 
compliance issues persist and results in treatment failures. Available pediatric antimalarial 
agents are available as suspensions, powders or as tablets to be crushed for reconstitution 
with water, all of which have poor acceptability among children. Malaria drugs tend to be 
bitter, tablets are difficult to swallow and even sweetened liquid formulations leave a bitter 
after taste. Injections which are used as a last resort present the problem of pain and therefore 
not practical for routine drug delivery, leaving the oral route as the most viable option.  
 However, like most other medications, clinical trials are not conducted in children and 
as a result, there are no antimalarial pediatric formulations, which therefore requires breaking 
of tablets, which in most cases result in dosing inaccuracies. Further, issues of poor stability, 
microbial contamination and inaccurate dosing in liquid alternatives are apparent due to the 
lack of appropriately designed pediatrics formulations for the African market. Given that 
most newly developed antimalarial drugs, eventually face the problem of ‘drug resistance’, 
indiscriminate and ineffective use of antimalarial drugs, especially for children, is a critical 
issue, requiring urgent attention. As part of its recommendations on rationale use of 
antimalarial drugs, the WHO notes the importance of promoting adherence to a full treatment 
course, which is however, significantly impeded by the bitter taste of most drugs, especially 
for children, resulting in high chances of poor treatment and development of more resistant 
and dangerous strains of the parasite
18
. Therefore, resolving the problem of poor pediatric 
patient acceptability through formulation (or re-formulation) and novel drug delivery 
approaches, seems to be a viable means of improving uptake and ultimately therapeutic 
outcomes. Current treatment options recommended by the WHO for treatment of 
uncomplicated malaria in children are summarized in Table 5. 
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TABE 5 HERE 
 
5 Remedies 
In response to the above challenges, the pharmaceutical industry and regulators have 
explored various formulation approaches to improving patient compliance, especially in the 
vulnerable geriatric and pediatric populations as discussed below. Most of these approaches 
involve re-formulation in the form of oral dosage forms as they’re the simplest and cheapest 
to produce and administer. 
 
5.1 Traditional remedies 
Liquids (solutions, suspensions)  
Solutions and syrups contain one or more solids dissolved in a suitable solvent, usually water 
or a mixture of miscible solvents such as water and ethanol or water and glycerol. Their key 
advantage is the assurance of uniform dosage administration because of the solutes being 
uniformly dispersed throughout the solution. Solutions are also more easily swallowed 
compared to tablets and capsules and are therefore the most popular dosage form, especially 
for children. However, use of solutions has major disadvantages, such as chemical, physical, 
or microbial instability (requiring a preservative), taste issues (requiring taste masking and 
flavoring agents), lack of controlled release properties, limited number of safe excipients, and 
unreliable dosing because of incomplete swallowing
20
 
 Unlike solutions, suspensions comprise two phases with solid particles dispersed 
within a liquid phase. The main reason for using suspensions is the poor solubility of the 
main active ingredient and also has the possibility of taste masking the drug within the 
particulate excipient mixture. They are used for various routes of administration including 
oral, topical or nasal. The most common oral suspensions tend to be prepared in the form of 
dry powders for reconstitution, which has the advantage of reducing the incidence of drug 
instability. Typical examples include antibacterial suspensions for children such as 
amoxicillin. Generally, measuring devices such as cups, syringes or spoons are required to 
ensure accurate dosing of liquids unlike tablets, which can be challenging for children on 
their own and for geriatric patients, especially those with conditions such as Parkinson’s 
disease. In the case of suspensions, patients need to remember to shake the bottle before use 
and suspending agents are required to ensure the drug particles remain suspended long 
enough to allow reproducible accurate dosing. 
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Semi-solids  
 The use of semi-solids is based on the principle of convenient food intake such as 
porridge and mashed food which are easily eaten by children in particular or adults with little 
or no teeth. Sometimes, powders or crushed tablets are either mixed with such semi-solid 
foods or hidden within them to avoid contact of the medication with the taste mechanisms 
(especially in children), and therefore improve patient acceptance. Common semi-solid 
formulations for oral delivery or local mucosa administration include gels and medicated 
gums
21
. 
 Medicated gums are semi-solid confectionary type dosage forms designed for 
chewing to release the drug into saliva
22
. They can deliver the active ingredient to elicit local 
action within the mouth (such as antibiotics to control gum disease) or for systemic 
absorption
23
 across the oral mucosa (buccal and sublingual) and / or gastrointestinal routes 
(e.g., nicotine). Medicated gums are traditionally manufactured using a melting process 
adapted from the confectionary industry but could also be obtained by directly compressing 
insoluble gum powder. Common gum bases include polyisoprene, polyisobutylene, 
isobutylene isoprene copolymer, styrene butadiene rubber, polyvinyl acetate, polyethylene, 
ester gums, and polyterpenes. Other excipients include plasticizers and softeners (e.g. 
glycerin and oleic acid) to maintain pliability, sweeteners, and flavoring agents to improve 
taste, and dyes to enhance appearance.  
 
Lozenges 
Lozenges contain one or more drugs contained within a solid dosage form designed to 
dissolve or disintegrate slowly in the mouth to release the active ingredient. In most cases, 
lozenges provide local action in the oral cavity or the throat but some (e.g. nitroglycerin) are 
intended for systemic absorption after dissolution. Common drug classes delivered in the 
form of lozenges include antiseptics, analgesics, decongestants, antitussives and antibiotics. 
Lozenges can be formulated with sugars such as sucrose and dextrose or sugar-free 
alternatives usually based on sorbitol or mannitol
21
. 
 
Soluble (orally disintegrating) tablets  
These are fast disintegrating tablets, usually containing highly water soluble additives or 
effervescent materials such as hydrogen carbonate, which easily dissolve or disintegrate 
rapidly in water, therefore allowing the patient to swallow in the form of a solution or 
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suspension
24-25
. They are manufactured by conventional tableting means or by using freeze-
drying or molding approaches. 
 
5.2 Novel drug delivery approaches  
Over the past few decades, there has been an increased interest in novel drug delivery 
systems driven by various factors including:  
• Therapeutic (clinical) concerns depending on whether the formulation in question is 
for self-administration, dosing schedule (daily versus weekly) or hospital use, 
preventive or therapeutic application, local or systemic delivery as well as age and 
disease state. 
• Biopharmaceutics factors such as route of administration which is affected by the 
patient, disease state and site of action.  
• Physico-chemical properties of the drug and dosage such as taste, color and 
appearance (size and shape) which determine patient acceptability. 
 These factors are important and are mainly aimed to improve safety, efficacy and 
patient compliance and ultimately help to increase product life cycle
26
. Liu and co-workers 
have suggested the use of fast melt formulations such as films and wafers for geriatric drug 
delivery as an alternative to traditional tablets, capsules and effervescent powders
7
.  
 
5.2.1 Minitablets  
These are flat or slightly curved tablets ranging in diameter from 1 – 3mm for easy 
administration, especially to children under the age of six who cannot take conventional 
tablets and are generally accepted by pediatric patients. In a randomized controlled trial in 
children, Klingmann and co-workers evaluated the acceptability of 2mm diameter mini-
tablets in comparison with standard syrup formulations. The ability of the children to swallow 
2mm mini-tablets (coated or uncoated) compared to 3ml of syrup was investigated. Their 
results showed that though all the formulations tested were generally accepted, the uncoated 
mini-tablets showed significantly higher acceptability than the syrup and concluded that 
mini-tablets are a suitable drug delivery alternative to syrups
27
. Biyyala and colleagues 
investigated mini-tablets in a GMP environment and concluded that “mini-tablets can allow 
flexible dosing across a wide pediatric age/weight range with just one dosage form” whilst 
they can be mixed with food or dispersed in liquid to improve patient acceptance
28
.  
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 Mini-tablets show great flexibility in terms of application and rate of drug disposition 
as they can be formulated to release the drug very quickly as well as in a controlled fashion or 
a combination of both. Lopes and co-workers compressed mini-tablets into a biphasic 
delivery system that was able to release a model drug in a zero order release fashion over a 
long period of 8 hours using different combinations of hydroxypropylmethylcellulose and 
ethyl cellulose
29
. On the other hand, orally disintegrating mini-tablets have been reported as 
novel solid drug delivery systems and noted to fulfil the ideal requirements of pediatric 
appropriate formulations including ease of administration, flexible (individual) dosing 
adaptation to suit the wide age range, good stability, low transport and storage costs  and 
excipients generally regarded as safe (GRAS)
30
.  
 
5.2.2 Fast dissolving films and tablets  
Fast-dissolving formulations generally disintegrate or dissolve within 1 minute when placed 
in the mouth in the presence of only saliva without the need for liquids or chewing. 
Compared to fast dissolving tablets, fast dissolving films and wafers are more recent 
formulations, designed for patients with fear of chocking (pediatric and geriatric) and in some 
cases used to achieve patent extensions
31
. Fast-dissolving films are thin polymeric sheets 
comprising various hydrophilic polymers usually plasticized and can be prepared by solvent 
casting of aqueous gels or extruding by hot-melting of the powdered mixture. The most 
common fast dissolving film commercially available are summarized in Table 6 below. 
Commonly used film forming materials investigated include pullulan, cellulose ethers, 
starches, gums such as xanthan, alginates, polyvinyl alcohols, polyvinylpyrrolidone and 
various combinations of the above
32-36
. Fast dissolving formulations normally always contain 
excipients such as dextrose or sucrose and microcrystalline cellulose, with high water 
affinity, which contributes to the rapid disintegration in the presence of saliva. Cilurzo and 
co-workers developed fast dissolving films containing maltodextrins for delivering a model 
insoluble drug, piroxicam using both solvent casting and hot melt extrusion approaches. The 
other excipients included glycerol as plasticizer as well as sorbitan monooleate and 
microcrystalline cellulose
37
. 
 Reiner and co-workers investigated the bioequivalence of a patented film formulation 
of ondansetron compared with the commercial oral dispersing tablets and showed similarities 
in various regulatory pharmacokinetic profiles. They suggested that compared to tablets, the 
fast dissolving film was easier to swallow without any need of water, no liquid intake was 
necessary as well as no flavor taste compared to syrups and finally they were easier to handle, 
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store and transported around, compared to the orally disintegrating tablets
38
. Khan and co, 
used supercritical fluid technology to convert swelling controlled omeprazole loaded 
Metolose based films into rapid release fast dissolving films for potential pediatric delivery. 
The supercritical fluid treated films released greater than 90% of the drug within 15 minutes 
compared to the original swelling films which released just over 60% even after one hour
39
. 
 
TABLE 6 HERE 
 
 Wafers on the other hand are highly porous solid dosage forms obtained by freeze-
drying of polymer solutions. Their highly porous nature allow very rapid ingress of saliva 
which enables them to disintegrate or dissolve in the presence of minimal volumes of saliva 
and form easily flowing gels that can be readily swallowed without the risk of chocking. The 
most common fast dissolving wafer commercially available is Zydis developed by Catalent, 
which dissolves on the tongue almost instantly upon contact with saliva. The company lists a 
range of applications and indications including dysphagia, pediatric and geriatric application, 
fast onset, and ease of use. Therapeutic indications include anti-psychotic (Parkinson’s 
disease, schizophrenia), anti-emetic (travel sickness), gastrointestinal (diarrhea, constipation), 
allergy (anti histamine, immunotherapy) and anxiolytic (anti-depressants)
41
. In a pilot clinical 
trial, an open label oral to Zydis switch study was conducted to investigate the tolerability of 
rapid switch from oral selegiline to Zydis selegiline for the treatment of Parkinson’s disease.  
Patients generally preferred the Zydis selegiline preparation but the authors concluded that 
the difference is unclear for any clinical significance given the open label nature of the trial
42
. 
Preis and co-workers evaluated taste-masked cetirizine hydrochloride formulated in oral 
freeze-dried matrix based on the Zydis technology. Their study showed that a resin of 
cetirizine HCl and various cyclodextrins were successfully incorporated into the Zydis 
freeze-dried formulation and yielded a stable product with good release profile in the 
presence of cyclodextrin
43
.  
 
5.2.3 Controlled release mucoadhesive films and wafers  
More recently, there has been interest in mucoadhesive formulations such as films and wafers 
for drug delivery across the non-keratinized oral (buccal and sublingual) mucosal membranes 
to achieve systemic effect without the need for swallowing whilst also avoiding first pass 
metabolism, which can allow the use of lower doses to reduce potential side effects. Due to 
the numerous advantages of buccal dosage forms, pharmaceutical companies have adopted 
Page 14 of 36Journal of Pharmaceutical Sciences
15 
 
various technologies to manufacture oral films on a large scale as an alternative to traditional 
dosage forms such as tablets and capsules
44
.  
 There have been several studies reported in the literature for such mucoadhesive 
formulations for various applications including pediatric and geriatric patients and for various 
indications and these are summarized in Table 7 below. The matrix usually comprises 
hydrophilic polymers with functional groups able to form suitable interactions with the mucin 
glycoproteins present on the buccal and sublingual mucosal surface, which ensures prolonged 
residence time to allow drug penetration through the membrane epithelium. 
 
TABLE 7 HERE 
 
5.3 Personalized medicine 
General drug development involves testing new drugs or products in subsets within 
populations without necessarily taking into consideration the genetic, physiological, 
biochemical, nutritional and personal variations between different (individual) patients
65
.  
This results in differences observed in therapeutic outcomes and even toxicities and side 
effects of administered therapies. Conventional dosage forms such as tablets or capsules, 
contain predefined amounts of active pharmaceutical ingredients with clinical trials testing 
undertaken using middle aged adult males. As a consequence, certain patient groups, 
particularly women, pediatric and geriatric patients could experience under- or over-dosage, 
which could result in reduced efficacy or side effects respectively. The objective of 
personalized medicine therefore is to individualize drug dosage that is specifically 
customized to the needs of an individual patient. This is important as several variables such 
as age, weight, height, race, gender and disease state of the individual patient, affect efficacy 
(and/or toxicity) and should therefore be considered and translated in precisely tailored oral 
delivery forms to allow for more individual-specific therapeutic effect.  
 With advances in molecular biology, biotechnology and bioinformatics tools, 
exemplified by the sequencing of the human genome, there has been a move towards 
designing drugs and dosage forms, tailored to the biochemical and physiological make-up of 
the patient, in a new field referred to as personalized medicine. The Personalized Medicine 
Coalition
66
 defines it as “the use of new methods of molecular analysis to better manage a 
patient’s disease or predisposition to disease”. The European Union
67
 defines it as “providing 
the right treatment to the right patient, at the right dose at the right time”. President’s Council 
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of Advisors on Science and Technology
68
 defines personalized medicine as “the tailoring of 
medical treatment to the individual characteristics of each patient.” The American Medical 
Association
69
 defines personalized medicine as “Health care that is informed by each 
person’s unique clinical, genetic, and environmental information”; whilst the National Cancer 
Institute, NIH
70
 defines personalized medicine as “a form of medicine that uses information 
about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease.”  
 The main advantage of personalized medicine as far as pediatric and geriatric patients 
are concerned, is that it avoids the ‘one-size-fits-all’ approach (Figure 2) which does not take 
into consideration the wide differences present within these patient groups as noted above. 
For example, pediatric patients are at different stages of development from birth right up to 
puberty whilst the bodies of geriatric patients begin to deteriorate at different rates and at 
different stages depending on age, lifestyle and body weight
71
. 
 
FIGURE 2 HERE 
 
5.3.1 Drug delivery approaches to personalized medicine 
 According to the FDA
71
, personalized medicine promises to increase benefits and 
reduce risks for patients by improving both the safety and efficacy of medicinal products. As 
a result, drugs need to be designed and delivered using appropriate formulations that ensure 
the drug reaches the intended target to achieve the desired therapeutic effect whilst at the 
same time being easy to administer for the patient, to reduce the chances of non-compliance, 
which can have severe consequences including complications and potential fatalities. Further, 
such dosage forms should as much as possible be able to be produced on a large scale as well 
as extemporaneously on a small scale in hospital pharmacies and dispensaries and within 
nurse clinics. This requires use of cheap and readily available excipients, approved by 
regulators such as the FDA and generally be regarded as safe (GRAS). Breitkreutz and Boos 
suggested that drug delivery to older patients require individualized dosing, patient adapted 
drug formulations and delivery devices to ensure specificity of drug efficacy
73
. In particular, 
highly potent active pharmaceutical ingredients with very narrow therapeutic windows, such 
as digoxin and morphine, require precise dose adaptation, including use of phased dose 
titration. This requires appropriate drug delivery systems to allow the selection and 
administration of individualized drug dose to be embedded into routine clinical pharmacy 
practice.  
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 Pardeike and co-workers investigated nano-suspensions as personalized oral dosage 
forms using a micro-dosing technology. This was based on inkjet-type printing technique 
where all the active pharmaceutical ingredients and excipients for an individual patient were 
directly printed on an edible substrate which was easily inserted into a hard gelatin capsule 
for oral administration
74
. The advantages of this technique as spelt out by the authors include 
(i) the possibility of on-demand manufacturing of a personalized oral dosage for individual 
patients, (ii) precise dosing of low-dose drugs and/or drugs with a small therapeutic window, 
(iii) multi-dosing by printing multiple drug layers on one paper carrier strip using barrier 
coatings and (iv) no need for the development of complex formulations (e.g. multilayer 
tablets)
74
. However, practical implementation and clinical studies are required to be able to 
confirm the effectiveness and success of these concepts. Current practices still involve dosing 
liquids by droppers, spoons and syringes or splitting tablets into segments, which clearly 
present various risks such as inaccurate dosing (Figure 3). Though multi-particulate dosage 
forms (pellets) dispensers have been developed, there is only one dispenser available on the 
market. Other technologies such as the Solid Dosage Pen has potential for individualize dose 
choices
73
.  
 
FIGURE 3 HERE 
 
6 Concluding remarks 
New developed drugs will need to be designed with the delivery to the required patient 
groups (including vulnerable groups such as geriatric / pediatrics) in mind and tailored 
accordingly. This will need to include considerations at phase II and III clinical trials in 
children and geriatric populations for already approved drugs that have passed stringent 
safety and quality checks, just for the purpose of accurate dose calibration. Of course this 
raises ethical dilemmas of administering therapy to one group of children, but not others. 
Therefore models that bioequivalently mimic pediatric populations need to be designed to 
avoid the need of risking drug administration to such vulnerable patient groups during 
clinical trials or possibly reduce the sample sizes required in such endeavors. 
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FIGURE LEGENDS 
Figure 1 The various absorption barriers and stages of loss encountered by a typical drug 
delivered in the form of an oral dosage form (e.g. tablet or capsule). 
 
Figure 2. Representation of the trial-and-error or one-dose-fits-all approach versus 
personalized medicine. [Reproduced from Xie and Frueh 2005)]
72
.  
 
Figure 3 Various dosage forms currently employed in personalized medicine drug 
therapeutics. Adapted from
65
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 Table 1 Advantages and limitations of traditional routes of administration 
Route Type of dosage 
form 
Advantages Disadvantages 
Oral   
• Tablets 
• Capsules 
• Liquids 
• Suspensions 
 
• It is the most commonly used 
route. 
• Cheap and very economical. 
• Administration does not require 
special skills. 
• Self-medication is possible. 
• This route is convenient.  
• This route is painless1. 
• Pediatric and geriatric patients have difficulty in swallowing.  
• Swallowing medication requires fluids and therefore the probability of nausea 
and vomiting is increased. 
• Absorption rate of the drug into the bloodstream after swallowing varies 
depending on gastric emptying rate. 
• Affected by intestinal and stomach secretions and pH
2
. 
• Therapeutic peptides and proteins deactivated by the presence of acidic 
(stomach) environment and proteolytic enzymes in the GI tract 3.  
• Subject to first pass metabolism in the liver
 4
. 
Parenteral 
(injections) 
• Solutions 
• Emulsions 
• Rapid access of drug to the site 
of action without the risk of first 
pass metabolism in the liver.  
• Lower drug doses required 
compared to the oral route.   
• Drug rapidly disperses to various 
part of the patient's body before 
experiencing first pass effect in 
the liver. 
• Most patients, predominantly infants and geriatrics, do not readily accept 
injections because of pain.  
• Rate of metabolism varies between patients and therefore repeated injections 
might be necessary which can increase the stress level in patients 1. 
Topical 
(dermal / 
skin) 
• Creams 
• Ointments 
• Suspensions 
• Emulsions / 
lotions 
• Powders 
• Practical approach for treating 
skin conditions 
 
• Does not always enable medication to penetrate deeply to provide a systemic 
effect.  
• The rate of drug uptake across the skin is slow and therefore cannot be used in 
emergency situations. 
• Continuous contact with air can cause either oxidation or contamination to 
change the properties of the drug.  
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Table 2: Selected common geriatric diseases and current clinical therapies 
Disease Therapy/management Dosage form(s) 
Alzheimer's Disease Cholinesterase inhibitors e.g. 
Donepezil 
Tablets, orally 
disintegrating tablets 
Arrhythmia of the Heart  Beta-blockers e.g. 
Propranolol 
Tablets 
Arthritis Disease modifying anti-
rheumatic drugs e.g. 
Cyclosporine 
Capsules, liquids 
Bedsores (pressure ulcers) Muscle relaxants e.g. 
diazepam 
Tablets 
Cancer  Chemotherapy, depending on 
type of cancer 
Tablets, injections 
Cataracts  Surgery - 
Cholesterol Statins e.g. atorvastatin Tablets 
Chronic Kidney Damage Diuretics e.g. furosemide Tablets 
Chronic Obstructive Pulmonary Disease  Mucolytics e.g. carbocisteine Tablets, capsules 
Diabetes (e.g. Type 2) Biguanides e.g. Metformin Tablets 
Glaucoma  Eye drops Liquid 
Hypertension (High Blood Pressure)  Beta-blockers e.g. atenolol 
Calcium channel blockers 
e.g. amlodipine 
Tablets 
Tablets 
Incontinence, Urinary  Antimuscarinics e.g. 
oxybutynin 
Tablets, syrup, 
topical gel / patch 
Lymphoma, Non-Hodgkin's  Chemotherapy (e.g. 
vincristine) in combination 
with steroids (e.g. 
prednisolone) 
i.v. injections 
Tablets,  
Macular Degeneration, Dry Supplements e.g. vitamins 
and minerals 
Tablets, capsules 
Multiple Sclerosis (MS)  Immunomodulators e.g. 
Fingolimod 
Capsules 
Osteoarthritis NSAIDS e.g. diclofenac Tablets, cream 
Osteoporosis Bisphosphonates e.g. 
alendronate 
Tablets 
Parkinson's Disease  Dopaminergic drugs e.g. 
levodopa 
- 
Stroke  Antiplatelets e.g. aspirin Tablets 
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Table 3 Selected common pediatric conditions and current therapies  
 
Disease Treatment Dosage form 
Chicken pox Paracetamol 
Kaolin 
Suspensions 
Suspensions 
Ear infections Antibiotics 
Paracetamol 
Oral liquids or ear drops 
Suspension 
Flu Paracetamol Suspension 
Gastroenteritis Oral salts Liquids 
Impetigo Antibiotics Oral liquids 
Skin cream 
Malaria Artemether + lumefantrine 
Artesunate + mefloquine 
Dihydroartemisinin + piperaquine 
Dispersible tablets 
Tablets 
Tablets 
Scarlet fever Antibiotics Suspensions 
Tonsillitis Paracetamol 
Ibuprofen 
Suspensions 
Sprays 
Lozenges 
Whooping cough Antibiotics Suspensions 
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Table 4 Different routes of drug administration and corresponding dosage forms for adults 
and pediatric patients. 
Administration routes Site of administration Dosage forms 
Oral Mouth 
Solution, syrup, suspension, 
emulsion, gels, powders, 
granules, capsules, tablets etc. 
Sublingual Under the tongue Tablets, troches or lozenges 
Buccal Between gum and cheek  
Orally disintegrating tablet, 
Film, lollipop, lozenges, 
chewing gum 
Topical (epicutaneous/ 
transdermal) 
Skin surface 
Aerosols, gels, pastes, lotions, 
creams 
Parenteral 
Vein, spine, skin, muscles, 
bones, arteries, heart, joint-fluid 
areas, joints 
Injections, implants, irrigation 
Rectal Rectum 
Ointments, powders, creams, 
suppositories, solutions 
Respiratory Nasal 
Aerosols, inhalations, sprays, 
gases 
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Table 5 Antimalarial combination therapies (ACT) currently recommended by the WHO
19
 for 
treating uncomplicated malaria. 
Type of ACT Available adult 
Formulations  
Available 
pediatrics 
formulations 
Target dose range Recommend
ed dose 
Artemether + 
lumefantrine 
Dispersible or 
standard tablets 
containing 20mg 
artemether and 
120mg 
lumefantrine 
Flavored 
dispersible tablet 
5–24mg/kg body weight of 
artemether and 29–144 
mg/kg body weight of 
lumefantrine 
Twice a day 
for 3 days 
(total of 6 
doses) 
Artesunate + 
amodiaquine 
Fixed dose 
combination tablet 
containing 25+ 
67.5mg; 50+ 
135mg; or 100+ 
270mg of 
artesunate and 
amodiaquine 
respectively 
None 4 (2–10mg/kg body weight 
per day artesunate and 10 
(7.5–15) mg/kg body weight 
per day amodiaquine. 
Daily for 3 
days 
Artesunate + 
mefloquine 
Tablets containing 
100mg artesunate, 
220mg, 
mefloquine 
hydrochloride (200 
mg mefloquine 
base) 
A fixed dose 
pediatric tablets 
containing 25mg 
artesunate and 
55mg 
mefloquine 
hydrochloride 
(50mg 
mefloquine base) 
4 (2–10) mg/kg body weight 
per day artesunate and 8.3 
(5–11)mg/kg body weight 
per day mefloquine 
Daily for 3 
days 
Artesunate + 
sulfadoxine 
/pyrimethamine 
Blister packed, 
scored tablets 
containing 50mg 
artesunate and 
fixed dose 
combination 
tablets containing 
500mg 
sulfadoxine+25mg 
pyrimethamine 
None 4 (2–10)mg/kg body weight 
per day artesunate and 25 
/1.25 (25–70 /1.25–3.5) 
mg/kg body weight 
sulfadoxine/ pyrimethamine 
Artesunate 
dose given 
daily for 3 
days. 
Sulfadoxine / 
pyrimethami
ne dose 
given as 
single dose 
on day 1. 
Dihydroartemisi
nin + 
piperaquine 
Fixed dose 
combination 
tablets containing 
40mg 
dihydroartemisinin 
and 320mg 
piperaquine. 
Pediatric tablets 
containing 20mg 
dihydroartemisin
in and 160mg 
piperaquine 
4 (2–10) mg/kg body weight 
per day dihydroartemisinin 
and 18 (16 – 27) mg/kg body 
weight per day piperaquine 
for 3 days for adults and 
children weighing > 25kg. 
4 (2.5–10)mg/kg body 
weight per day 
dihydroartemisinin and 24 
(20– 32)mg/kg body weight 
per day piperaquine for 3 
days for children weighing < 
25kg. 
Daily for 3 
days 
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Table 6 Examples for fast dissolving films commercially available on the market (y = years, 
m = months) (Reproduced from Slavkova and Brietkreutz, 2015)
40 
Indications API Product Age Company 
Mouth freshener Mint oil Listerine n.d. Pfizer 
Flatulence, 
nausea 
Silicone oil Gas-X-Tongue 
Twisters 
≥ 0 y Gas-X 
Nicotine 
withdrawal 
symptoms 
Nicotine NiQuitin Strips ≥ 12 y GSK 
Iron deficiency, 
anemia 
Ferric oxide 
Folic acid 
Hemoramin ≥ 18 y C.L. Pharm 
Chemotherapy 
induced nausea 
and vomiting 
Ondansetron Setofilm 
Zuplenz 
≥ 6 m 
≥ 4 y 
Norgine/tesa Labtec 
Galena Biopharm 
Migraine Zolmitripan Zolmitriptan 
Renantos 
≥ 18 y Renantos 
Schizophrenia Risperidone Risperidon HEXAL 
SF 
≥ 4 y Hexal/Sandoz 
Alzheimer’s 
disease 
Donezepil 
Hydrochloride 
Donezepil-HCl 
HEXAL SF 
≥ 18 y Hexal/Sandoz 
Erectile 
dysfunction 
Sildenafil citrate Sildenafil Sandoz  
Sedera 
≥ 18 y Sandoz 
C.L. Pharm 
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Table 7. Summary of published buccal and sublingual drug delivery systems 
 
Drug Formulation / Reference 
Paracetamol, indomethacin Film45 
Rizatriptan benzoate Film
46 
Insulin Film
47 
Insulin Film48 
Nicotine Film49 
Zolmitriptan Film
50 
Lidocaine Patch
51 
Omeprazole Film52 
BSA Wafer53 
BSA Xerogels
54
 
BSA Wafer
55
 
BSA Wafer56 
BSA Wafer57 
Insulin Xerogels
58 
Ibuprofen, paracetamol Wafer59 
Nicotine Films / wafers60 
Nicotine Films / wafers
61 
Omeprazole Films
62 
Ondansetron Films63 
Lidocaine hydrochloride Films64 
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Figure 1  
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Figure 2  
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Figure 3  
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